World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   97 records for 21 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3
Recruitment statusMain ID Public TitleDate of Registration
Not RecruitingCTRI/2015/03/005597
To compare the effect of Tiotropium 5 ug and Olodaterol 5 ug in fixed dose combination over Tiotropium 5 ug in reducing Moderate to severe worsening of a disease in patients with severe to very severe Chronic Obstructive Pulmonary disease
02-03-2015
AuthorisedEUCTR2014-002275-28-FI
Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-002275-28-ATComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.27/11/2014
AuthorisedEUCTR2014-002275-28-DKComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.13/11/2014
AuthorisedEUCTR2014-002275-28-GRComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.29/01/2015
AuthorisedEUCTR2014-002275-28-SIComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.22/01/2015
AuthorisedEUCTR2014-002275-28-IEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.28/11/2014
AuthorisedEUCTR2014-002275-28-ITComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.28/10/2014
AuthorisedEUCTR2014-002275-28-LTComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.29/12/2014
AuthorisedEUCTR2014-002275-28-HUComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.19/11/2014
AuthorisedEUCTR2014-002275-28-LVComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.05/01/2015
AuthorisedEUCTR2014-002275-28-HRComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.02/04/2015
RecruitingNCT02296138Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.19/11/2014
AuthorisedEUCTR2014-002275-28-BEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.18/11/2014
AuthorisedEUCTR2014-002275-28-PTComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.10/11/2014
AuthorisedEUCTR2014-002275-28-NLComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.18/11/2014
28/10/2014
AuthorisedEUCTR2013-000490-79-ES
Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 22/05/2014
Not RecruitingEUCTR2010-022134-89-HU
Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2010-022134-89-SIEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.15/11/2013
AuthorisedEUCTR2010-022134-89-ESEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.01/10/2013
AuthorisedEUCTR2010-022134-89-ITEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.20/09/2013
Not RecruitingEUCTR2010-022134-89-NLEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.04/10/2013
Not RecruitingEUCTR2010-022134-89-EEEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.14/10/2013
Not RecruitingEUCTR2010-022134-89-LTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.24/10/2013
Not RecruitingEUCTR2010-022134-89-DKEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.23/01/2014
AuthorisedEUCTR2010-022134-89-ATEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.03/02/2014
AuthorisedEUCTR2010-022134-89-HREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.29/08/2014
AuthorisedEUCTR2010-022134-89-PTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/09/2014
AuthorisedEUCTR2010-022134-89-GREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/01/2014
AuthorisedEUCTR2010-022134-89-CZEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/10/2013
11/09/2013
RecruitingNCT01830647
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
10/04/2013
RecruitingNCT01707992
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003647-30-ESA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).29/10/2012
AuthorisedEUCTR2012-003647-30-GRA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).14/11/2012
AuthorisedEUCTR2012-003647-30-ITA multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)11/01/2013
AuthorisedEUCTR2012-003647-30-ATA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).07/02/2013
AuthorisedEUCTR2012-003647-30-BEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).08/10/2012
AuthorisedEUCTR2012-003647-30-BGA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).10/05/2013
AuthorisedEUCTR2012-003647-30-SKA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).20/02/2014
AuthorisedEUCTR2012-003647-30-GBA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).23/10/2012
AuthorisedEUCTR2012-003647-30-CZA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).28/11/2012
AuthorisedEUCTR2012-003647-30-EEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).19/11/2012
AuthorisedEUCTR2012-003647-30-LVA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-PLA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).12/02/2013
AuthorisedEUCTR2012-003647-30-DEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-HUA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
28/09/2012
Not recruitingNCT01667380
An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)
13/08/2012
Not recruitingNCT01617005
An Observational Study of RoActemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Non-Biological DMARDs
08/06/2012
RecruitingNCT01533207
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery 11/02/2012
AuthorisedEUCTR2011-005328-17-IE
A study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2011-005328-17-ESA two-arm, non-randomized, multicenter, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer15/02/2012
AuthorisedEUCTR2011-005328-17-ITA TWO-ARM, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED-AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE Her2-positive early breast cancer29/03/2012
AuthorisedEUCTR2011-005328-17-GRA two-arm, non-randomized, multicenter, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer11/04/2012
AuthorisedEUCTR2011-005328-17-SIA two-arm, non-randomized, multicenter, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer31/05/2012
AuthorisedEUCTR2011-005328-17-FIA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2- positive early breast cancer25/06/2012
AuthorisedEUCTR2011-005328-17-GBA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer06/03/2012
AuthorisedEUCTR2011-005328-17-HUA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer27/02/2012
AuthorisedEUCTR2011-005328-17-SEA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer13/09/2012
AuthorisedEUCTR2011-005328-17-LTA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer23/04/2012
AuthorisedEUCTR2011-005328-17-PLA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2- positive early breast cancer16/05/2012
AuthorisedEUCTR2011-005328-17-PTA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2- positive early breast cancer01/03/2012
AuthorisedEUCTR2011-005328-17-DEA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer15/02/2012
AuthorisedEUCTR2011-005328-17-NLA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2- positive early breast cancer29/06/2012
AuthorisedEUCTR2011-005328-17-CZA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer13/02/2012
AuthorisedEUCTR2011-005328-17-BGA study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer27/06/2012
RecruitingNCT01566721A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)22/03/2012
RecruitingDRKS00004499A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]30/11/2012
09/02/2012
    
1 2 3
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history